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http:WHAT THIS PAPER ADDS
Endovascular treatment of challenging TASC C and D femoropopliteal lesions has become routine practice in
many centers. However, the high rates of stent fractures related to these procedures remain a concern.
Moreover, the real clinical impact of these fractures is still a matter of debate in the literature. The aim of this
study is to shed light on the incidence and the clinical impact of stent fractures in a single center prospective
cohort of severely-diseased patients.Background: The clinical impact of stent fractures is still controversial. This study analyzed the incidence and the
clinical impact of stent fractures after stenting of long femoropopliteal lesions.
Methods: From November 2008 to October 2009, 58 patients (62 limbs) were treated in a single center with a
primary nitinol self-expanding stent for Trans-Atlantic Inter-Consensus (TASC) C and D de novo femoropopliteal
lesions. Patients were prospectively followed by medical and duplex scan examinations. Stent fractures were
assessed by biplane X-rays at 12 months. Logistic regression analysis was performed.
Results: At 1 year a complete follow-up was obtained in 42 limbs/90 stents. The median length of the stented
segment was 240  180 cm with a mean of 2.1 (1e4) stents per patient. Sixteen stents (17.8%) were fractured:
one type I (asymptomatic); seven type II (2 restenosis); ﬁve type III (asymptomatic), and three type IV stent
fractures (1 restenosis). Stent diameter (p¼ .04) and stent implantation in the distal part of the superﬁcial femoral
artery (p ¼ .05) were positively associated with stent fractures. Stent fracture had no inﬂuence on restenosis.
Conclusion: This study suggests that the high stent fracture rate associated with endovascular treatment of long
femoropopliteal lesions should be balanced with its low clinical impact.
 2013 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Endovascular treatment as the ﬁrst therapeutic option even
for most challenging Trans-Atlantic Inter-Consensus (TASC)
C and D superior femoral artery (SFA) lesions has become
routine practice. Long length stenting, however, may result
in a high rate of stent fractures. The exact clinical impact of
these fractures remains subject to controversy The associ-
ation between stent fractures, in-stent restenosis (ISR), and
clinical deterioration is still a matter of debate and the
actual recommendations on endovascular SFA treatment
are challenged by the most recent reports.1,2 According to
the literature, the incidence of stent fractures rangesrresponding author.
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//dx.doi.org/10.1016/j.ejvs.2013.05.010between 2% and 65%.3 Stent fracture rates vary widely
depending on factors such as the severity of the treated
lesions.4e6 We recently reported that primary stenting of
TASC C and D femoropopliteal lesions as ﬁrst choice treat-
ment was safe and resulted in high sustained clinical
improvement at 1 year.7 We now aim to evaluate the
incidence of stent fractures in a prospective cohort of
severely diseased patients and its clinical relevance.
METHODS
From November 2008 to October 2009, patients presenting
with de novo femoropopliteal TASC C and D lesions longer
than 15 cm were prospectively enrolled. Endovascular
therapy was the ﬁrst-intention treatment. Detailed design
of this single-center follow up cohort have been previously
published.7 Patients had either one or two limbs treated.
The protocol was approved by the local ethics committee
and all patients gave informed consent.
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The procedure was performed under local anesthesia with
conscious sedation unless general anesthesia was required.
Access to the culprit lesion was achieved either by way of
an antegrade femoral puncture or by a contralateral
approach with the use of a 6F sheath or a 6F guide sheath
(45 cm) (Destination, Terumo, St Quentin, France), respec-
tively. Patients were administered intravenous heparin
bolus (50 IU/kg). Once lesions were catheterized or recan-
alized, primary stenting was preferably performed unless
predilation with a 3-mm balloon was necessary because of
highly calciﬁed lesions. No re-entry device was used.
Stenting length exceeded lesions length by 5- to 10-mm
proximally and distally. The maximal available length of
the LifeStent (C.R. Bard Peripheral Vascular, Tempe, AZ,
USA) was 170 mm. Lesions were treated with as few stents
as possible. Adjacent stents overlapped by 1 cm. The total
stenting length was reported by adding the length of the
implanted stents. We only used the self-expandable Life-
Stent of either 6 mm or 7 mm diameter. The nominal stent
diameter was chosen to be the same as the reference vessel
diameter. Then stents were routinely postdilated to ensure
optimal extension and apposition. The PTA balloon diam-
eter (Optapro, Cordis, Bridgewater, NJ, USA) was chosen so
that the nominal diameter was 1 mm narrower than the
vessel diameter to reduce medial damage8 and so that the
balloon length does not exceed that of the stent. Every
associated inﬂow or outﬂow lesions suspected to be
involved in the disease were treated during the same pro-
cedure. Groin closure was accomplished via manual
compression and, for day case procedures, using a vascular
closure device (Angioseal, St Jude Medical, Boulogne-
Billancort, France). The usual antiplatelet regimen was not
discontinued before the procedure. No antiplatelet bolus
was administrated prior to the procedure. If no puncture-
related hematoma or bleeding was observed in the recov-
ery room, the patient was administered a bolus of 250 mg
of aspirin. During hospitalization patients were given a
prophylactic dose of low-molecular-weight heparin. Dual
antiplatelet therapy was prescribed for a 6-month period
(aspirin, 75e160 mg/day and clopidogrel, 75 mg/day) after
which patients continued with only one antiplatelet agent
(APA).2,9 When patients were under oral antigoagulant
treatment, aspirin was the only APA added.Follow-up and outcomes
Stent fractures were assessed by biplane X-rays at 12
months with two different projections separated by at least
45 using the highest available magniﬁcation. An indepen-
dent core laboratory (CoreLab, Bad Krozingen, Germany)
analyzed X-rays for stent fractures. Magniﬁcation of the
images was utilized in any case in which stent strut fracture
was suspected using QVA software (Medis medical imaging
systems, Leiden, The Netherlands). Stent fractures were
assessed by a medical advisor according to standardized
classiﬁcation.10,11 A type 1 stent fracture was a single strut
fracture; a type 2 stent fracture was a multiple single stentfractures occurring at different sites or a multiple strut
fractures with V-form division of the stent; a type 3 was a
complete transverse linear fracture but without displace-
ment; and a type 4 was a complete transverse linear type 3
fracture with stent displacement.
Besides, each and every stent was identiﬁed in our
database by its length and diameter. In addition to these
basic characteristics, the anatomical location of each stent
was noted. To this end, the femoral artery was divided in
three portions (proximal, mid and distal third of the SFA);
the popliteal artery was also divided in three segments: P1
(above-knee popliteal artery), P2 (popliteal artery segment
in regard of the knee joint) and P3 (below-the-knee popli-
teal artery). Every stent was also associated with its number
of overlap(s). In case of a stent fracture, the exact anatomic
location of the fracture (proximal, mid or distal part of the
SFA or P1, P2 P3 portion of the popliteal artery) was noted
as well as the position of the fracture on the stent (prox-
imal, mid or distal third of the stent) and the number of
fractured stents in cases of multiple-stent implantation.
Clinical impact evaluation including symptom change
according to the Rutherford classiﬁcation, ankle brachial
index (ABI) measurement, and duplex scan examination was
performed at 1, 3, 6, 9, 12, and 18 months and yearly
thereafter. Major adverse clinical events (MACEs) were
intentionally sought and the hospital database was
searched for any additional relevant information. When
several fractures were observed on different individual
stents but on the same limb, all fractures were taken into
account in the ﬁnal stent fracture rate. When several frac-
tures were present on the same stent, only the most severe
fracture was considered. Data were recorded prospectively
in a database. Logistic organization was provided by two
clinical research ofﬁcers. Technical success was deﬁned as
achieving a ﬁnal residual diameter stenosis of <30% on the
procedural completion angiogram. Minor complications are
those following the procedure (within the ﬁrst month) but
not requiring further treatment and not extending hospital
stay. Major complications required re-intervention or delay
(more than 24 hours) in patient discharge. Primary sus-
tained clinical improvement was deﬁned as a sustained
upward shift of 1 category of the Rutherford classiﬁcation
for claudicants and by wound healing and rest pain reso-
lution for patients in critical limb ischemia (CLI), without the
need for repeated target lesion revascularization (TLR) in
surviving patients. Secondary sustained clinical improve-
ment was deﬁned as primary sustained clinical improve-
ment including the need for repeated TLR. Primary patency
was deﬁned as patency without any percutaneous or sur-
gical intervention in the treated segment or in the adjacent
areas. TLR expresses the frequency of the need for repeated
procedures (endovascular or surgical) due to a problem
arising from the lesion (þ1 cm proximally and distally to
include edge phenomena) in surviving patients with pre-
served limb. ISR was assessed by duplex ultrasound and was
deﬁned by restenosis of more than 50%. A peak systolic
velocity (PSV) ratio (intrastenotic/prestenotic) of 2.4 or
more was considered to be indicative of a restenosis of
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stent thrombosis was made when stent occlusion was noted
on duplex scan without any sign of stent restenosis on
previous duplex scan examinations. Patients were
rescheduled for reintervention in cases of recurrence of
symptoms or diagnosis of evolutive ISR on two consecutive
duplex scans.Statistical analysis
Results of statistical analysis were reported prospectively on
an intention-to-treat basis. Continuous variables were pre-
sented as mean and standard deviation (SD), median with
interquartile ranges (IQR), categorical variables as count,
and percentage. Demographic and comorbidity data were
recorded per patient and patency data were calculated on a
per limb basis. Survival rate curves for TLR/TER (target ex-
tremity revascularization) were plotted and calculated using
the KaplaneMeier method. For patients who died before
the ﬁnal follow-up examination or for patients lost to
follow-up, the status of the last follow-up examination was
recorded. Logistic regressions with random effects were
used to analyze stent fracture prognosis factor and in-stent
restenosis predictive factors. Univariate analysis of major
cardiovascular risk factors, associated co-morbidities, med-
ications, lesions, and periprocedural intervention charac-
teristics were performed on the stent fracture endpoint. In
particular, the anatomical location of stent fractures, the
length and diameter of the implanted stent, the total
stented length, the number of implanted stents and corre-
sponding overlap, and the presence of calciﬁcations were
thoroughly analyzed in relation to stent fracture occurrence.
In a second step, variables with p < .25 in univariate
analysis were included in multivariate logistic regression
analysis with random effects.
A p value <.05 was considered statistically signiﬁcant.
Data were analyzed using SPSS software (SPSS Inc., Chicago,
IL, USA) and SAS software version 9.3.
RESULTS
Cohort
Over 1 year, 58 patients (62 limbs, 134 nitinol stents) were
prospectively enrolled for de novo femoropopliteal super-
ﬁcial lesion treatment. At the 1-year follow up data-point, X-
ray data that qualiﬁed for CoreLab analysis were available
for 41 (71%) patients (42/68% limbs, 90/67% stents).
Five patients (5 limbs) died before X-ray, one patient (2
limbs) was lost to follow up, two patients (2 limbs) were in
the palliative treatment unit and X-ray follow-up was not
undertaken due to their physical condition, one patient
underwent major amputation before X-ray control, and in
10 cases the quality of X-ray was insufﬁcient to be analyzed
(Fig. 1).Patients, lesions, and intraoperative data
Mean age was 70.5  11.7 years with a majority of male
treated (73.2%), 41.5% of the patients had diabetes mellitusand 21.4% had chronic renal failure (Table 1). According to
the American Society of Anesthesiologists (ASA) score, 18
(43.9%) patients were ASA 2, 22 (53.7%) were ASA 3, and
one (2.4%) was ASA 4. In 62% of the cases, patients pre-
sented with CLI. Lesions were TASC C in 66.7% and TASC D
in 33.3% of the cases (Table 2). The median length of the
lesions was 210  160 mm (150  65 mm for TASC C and
355  130 mm for TASCD) for a median total stented length
of 240  180 mm (180  80 mm for TASC C and
395  140 mm for TASC D). In three cases, the presence of
a highly calciﬁed lesion necessitated the use of a 3 mm
diameter predilation balloon to ensure optimal stenting.
Procedures required a mean number of 2.1  0.8 stents (11
legs with 1, 15 legs with 2, 15 legs with 3, and 1 leg with 4
stents) and in 69% of the cases the popliteal artery was
involved in the stented segment. Because patients
frequently presented with multilevel disease, concomitant
procedures were realized in 15 (35.7%) of the cases. Thir-
teen out of the 15 concomitant interventions (86.7%) were
endovascular procedures (1 common iliac artery stenting, 1
internal iliac artery stenting, 4 external iliac stentings, 1
common femoral artery stenting, 6 below the knee angio-
plasties) and the two others (13.3%) were open surgery
procedures (2 common femoral endarterectomies).
In the majority of the cases, patients were under statins
(78%) and under two APA regimens (61%) unless they were
already taking vitamin K antagonists (VKAs). In this latter
case, low-dose aspirin was the only APA prescribed.Stent fractures
At 1 year, 90 femoropopliteal nitinol stents were available
for analysis. Sixteen (17.7%) showed fractures. Five stents
presented with multiple fractures (3 stents with 2 type 4
fractures, 1 stent with 2 type 2 fractures, 1 stent with 1 type
3 and 1 type 2 fractures) (Table 3). In term of limbs, stent
fractures were detected in 15 (35.7%) of the 42 treated
limbs. In one limb, two different stents were fractured. In
the other limbs, only one stent was fractured. No fracture
was reported in the stent overlap zone. According to the
Jaff classiﬁcation,10 one type 1, seven type 2, ﬁve type 3,
and three type 4 fractures were observed (Fig. 2 and
Table 3). The type 1 stent fracture was not associated with
adverse clinical events. Among type 2 stent fractures, two
fractures were associated with symptomatic ISRs that were
diagnosed on duplex scan examination. Symptoms were
resurgence of claudication in the two cases. Both patients
underwent a TLR procedure and were asymptomatic at 1
year of follow-up. All limbs with type 3 stent fractures were
asymptomatic, though two of them presented an asymp-
tomatic ISR. Finally, of the three type 4 stent fractures, two
patients developed symptoms. One was claudicant versus
CLI at baseline due to an ISR. He underwent a TLR and was
asymptomatic at 1-year follow-up examination. The second
patient also suffered from claudication versus CLI at base-
line due to stent thrombosis. A redo endovascular proce-
dure under local anesthesia was undertaken. Despite
successful recanalization and iterative balloon inﬂations,
58 patients/ 62 limbs/ 134 stents 
41 patients/ 42 limbs/ 90 stents 
Death : 5 limbs 
Lost to follow up : 2 limbs (1 patient) 
Patients in palliative treatment unit*:  2 
limbs (2 patients) 
Major amputation: 1 limb 
X-ray invalid for CoreLab analysis:
10 limbs 
14 patients 
with > 1 stent 
fracture
15 limbs 
with > 1 
stent
fracture
16 stent 
fractures
Figure 1. Study ﬂowchart. *X-ray follow-up was not realized for these patients due to their very poor physical condition.
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direct patency could not be restored. This patient did not
present with CLI symptoms and was at high surgical risk and
was thus treated conservatively. He was considered not
improved at the 1-year clinical evaluation. Comparison of
the stents presenting with or without stent fracture was
realized. Several factors were assessed (Table 4). This
comparison showed that median individual stent length was
higher in the group of stents with (170  10) than without
(120  90) fractures (p ¼ .02). In line with this result, 170-
mm-long stents were used in 75% of the cases in the
fractured stent group compared with 35% of the cases in
the non-fractured stent group (p ¼ .005). The use of 7-mm-
diameter stents was more frequent in the fractured stent
group (44%) than non-fractured stent group (15%)
(p ¼ .01). Finally, stents with fractures were more
frequently found to be implanted in the distal third of the
SFA and in the proximal (P1) portion of the popliteal artery
(94% vs. 57%, p ¼ .005 and 63% vs. 31%, p ¼ .02),
respectively. No difference was noted in terms of arterial
calciﬁcation, number of implanted stents, and overlap be-
tween the groups of fractured and non-fractured stents.
Univariate logistic regression analysis with random effects
showed that stent diameter, stent length, and stent im-
plantation in the distal SFA and in the P1 segment of the
popliteal artery were signiﬁcantly associated with the risk ofstent fracture (p < .05, data not shown). Then multivariate
logistic regression analysis was performed for stent diam-
eter, stent length, distal SFA, and P1 implantation of the
stents and the number of stents (Table 5). This last analysis
showed that the use of large diameter stents (7 vs. 6 mm)
(OR, 18.9; 95% CI, 2.7e133; p ¼ 0.04) and stent implan-
tation in the distal third of the SFA (OR, 11.8; 95% CI, 1.01e
138; p ¼ .05) were positively associated with the onset of
stent fractures. A tendency towards association between
stent implantation in the proximal part of the popliteal ar-
tery (P1 segment) and stent fractures was noted, but
without reaching statistical signiﬁcance (p ¼ .07). Univariate
logistic regression analysis with random effects showed that
the number of stents and TASC C versus D lesions were
signiﬁcantly associated with restenosis (p < .05, data not
shown). Multivariate analysis including all the variables with
p < .25 in univariate analysis was then performed, and no
factor was found to be associated with restenosis. In
particular, stent fractures did not seem to have inﬂuence on
restenosis (Table 6).Clinical impact of fractures
Fractures occurred in 15 limbs (35.7%). Cerebrovascular
disease was more frequent in the group of patients with
stent fractures than in the group of patients without stent
Table 1. Patients demographic characteristics, cardiovascular risk factors, associated co-morbidities and medications.
Overall, n ¼ 41 Fractures, n ¼ 14 No fracture, n ¼ 27 p-Valuea
Demographics
Age mean  SD 70.5  11.7 68.0  12.3 71.8  11.4 0.33
Male, n (%) 30 (73.2%) 11 (78.6%) 19 (70.4%) 0.72
Cardiovascular risk factors
HT, n (%) 37 (90.2%) 12 (85.7%) 25 (92.6%) 0.60
Dyslipidemia, n (%) 22 (53.7%) 7 (50.0%) 15 (55.6%) 0.73
Diabetes mellitus, n (%) 17 (41.5%) 5 (35.7%) 12 (44.4%) 0.59
Smoking, n (%) 24 (55.5%) 9 (64.3%) 15 (55.6%) 0.59
Obesity, n (%) 20 (48.8%) 8 (57.1%) 12 (44.4%) 0.44
CRF, n (%) 9 (21.4%) 4 (26.7%) 5 (18.5%) 0.69
CAD, n (%) 22 (53.6%) 6 (42.8%) 16 (59.3%) 0.32
CHF, n (%) 8 (19.5%) 1 (7.1%) 7 (25.9%) 0.69
Cerebral vascular disease, n (%) 7 (17.1%) 5 (35.7%) 2 (7.4%) 0.035
ASA score
2, n (%) 18 (43.9%) 8 (57.1%) 10 (37%) 0.09
3, n (%) 22 (53.7%) 5 (35.7%) 17 (63%)
4, n (%) 1 (2.4%) 1 (7.1%) 0 (0%)
Medication
1 APA, n (%) 16 (38.1%) 6 (40%) 10 (37%) 0.72
2 APA, n (%) 25 (61%) 8 (57.1%) 17 (63%) 0.72
VKA, n (%) 9 (21.9%) 5 (35.7%) 4 (14.8%) 0.23
Statin, n (%) 32 (78%) 13 (92.8%) 19 (70.4%) 0.13
CEI, n (%) 28 (68.3%) 9 (64.3%) 19 (70.4%) 0.73
HT ¼ hypertension; CRF ¼ chronic renal failure; CAD ¼ coronary artery disease; CHF ¼ chronic heart failure; ASA score¼ American society
of anesthesiologists score; APA ¼ antiplatelet agent; VKA ¼ vitamin K agent; CEI ¼ conversion enzyme inhibitor.
a t-test for continuous variables, chi square or Fisher exact test for categorical variables.
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between the two groups in terms of demographic charac-
teristics, cardiovascular risk factors, and medication were
noted. In particular, no inﬂuence of statins, APA regimen or
VKA treatment was noted. (Table 1) The presence of stent
fractures did not signiﬁcantly inﬂuence the sustained clinical
improvement of limbs nor did it inﬂuence the patency of
the stented segment. Indeed, according to KaplaneMeier
estimates, primary sustained clinical improvement was 80%
in the group with stent fractures and 74.1% in the group
without stent fractures (Fig. 3A). Likewise, secondary sus-
tained clinical improvement was 91.6% in the group with
stent fractures and 91.7% in the group without stent frac-
tures (Fig. 3B). Primary patency was 60% in the group with
stent fractures and 74.1% in the group without stent frac-
tures while secondary patency was 80% and 88.2%,
respectively (Fig. 4A, B). At baseline, according to the
Rutherford (R) category, patients were R3 in 16 (38.1%)
cases, R4 in 10 (23.8%) cases, R5 in 12(28.6%) cases, and R6
in 4 (9.5%) cases. In contrast, at 12 months, 30 limbs
(71.4%) were classiﬁed as R0, 5 (11.9%) as R1, 4 (9.5%) as
R2, 2 (4.8%), as R3 and only 1 (2.4%) as R5. Accordingly,
baseline and 1-year mean ABI were 0.6  0.1 and 1.0  0.2,
respectively.DISCUSSION
In this study we reported prospectively the incidence and
the clinical impact of stent fractures after primary stenting
for TASC C and D femoropopliteal lesions. At 1-year, 16stents were fractured (17.8% in a stent-based analysis,
35.7% in a limb-based analysis). Using multivariate logistic
model, stent diameter (7 vs. 6 mm) and stent implantation
in the distal part of the SFA were signiﬁcantly associated
with occurrence of stent fracture (p ¼ .04 and p ¼ .05,
respectively). However, stent fracture was not associated
with recurrence of symptoms, ISR, or stent thrombosis.
Finally, there was a trend towards a better primary patency
in the absence of stent fracture but without reaching sta-
tistical signiﬁcance.Incidence of stent fractures
Stent fracture rates range between 2% and 65% in the
literature with various factors inﬂuencing stent fracture
rates.3 First of all, reported stent fracture rates vary greatly
according to the method of analysis. In the present study,
the stent fracture rate was 35.7% (15 fractures, 42 limbs) in
a limb-based analysis, and 17.8% in a stent-based analysis
(16 fractures and 90 stents). Most studies report their stent
fracture rates according to the number of the treated
limbs.2,5,14,15 In our opinion, the stent-based analysis seems
more relevant, particularly in long lesions with several
implanted stents, in order to reﬂect the result of each
implanted device. Of note, ﬁve stents developed multiple
fractures (3 stents with 2 type 4 fractures, 1 stent with 2
type 2 fractures, 1 stent with 1 type 3 and 1 type 2 frac-
tures) (Table 4). These fractures were in all cases close to
each other and probably related to the same mechanical
stress. Consequently, and in order to ﬁt with the regression
Table 2. Lesions and periprocedural intervention characteristics.
Overall, n ¼ 42 Fractures, n ¼ 15 No fracture, n ¼ 27 p-Valuea
Lower limb status
Baseline ABI, mean  SD, (n ¼ 22) 0.6  0.1 0.6  0.1 0.6  0.1 0.19
TASC C (n ¼ 13) 0.5  0.1 0.6  0.1 0.5  0.1
TASC D (n ¼ 9) 0.6  0.1 0.6  0.1 0.6  0.2
12 months ABI, mean  SD, (n ¼ 32) 1.0  0.2 1.0  0.2 1.0  0.2 0.62
TASC C (n ¼ 24) 1.0  0.2 1.0  0.1 1.0  0.2
TASC D (n ¼ 11) 0.9  0.2 0.9  0.2 0.8  0.2
Baseline Rutherford category
3 16 (38.1%) 7 (46.7%) 9 (33.3%) 0.34
4 10 (23.8%) 5 (33.3%) 5 (18.5%)
5 12 (28.6%) 2 (13.3%) 10 (37.0%)
6 4 (9.5%) 1 (6.7%) 3 (11.1%)
12 months Rutherford category
0 30 (71.4%) 11 (73.3%) 19 (70.4%) 0.68
1 5 (11.9%) 2 (13.3%) 3 (11.1%)
2 4 (9.5%) 1 (6.7%) 3 (11.1%)
3 2 (4.8%) 1 (6.7%) 1 (3.7%)
5 1 (2.4%) 0 (0%) 1 (3.7%)
Lesion characteristics
TASC C, n (%) 28 (67%) 7 (47%) 21 (78%) 0.04
TASC D, n (%) 14 (33%) 8 (53%) 6 (22%)
Lesion length (mm), median  IQR 210  160 290  200 160  120 0.10
TASC C 150  65 150  80 150  50
TASC D 355  130 340  95 380  180
Total stented length, median  IQR 240  180 320  220 200  150 0.21
TASC C 180  80 170  100 180  60
TASC D 395  140 385  105 420  180
Number of stent, median  IQR 2.1  0.8 2.3  1 2.1  0.8 0.51
TASC C 2.0  1.0 1.0  2.0 2.0  1.0
TASC D 3.0  1.0 3.0  1.0 3.0  0.0
Procedural characteristics
Predilation 3 (7.1%) 1 (6.7%) 2 (7.4%) 0.71
Associated angioplasty, n (%) 13 (31%) 5 (33.3%) 8 (30%) 0.53
Associated surgery, n (%) 2 (5%) 2 (13%) 0 (0%) 0.12
Major complications, n (%) 4 (10%) 3 (20%) 1 (4%) 0.08
Minor complications, n (%) 5 (12%) 4 (27%) 1 (4%) 0.05
Contrast (mL), mean  SD 80  28 77  26 82  30 0.66
Irradiation (mGy/m2), mean  SD 3.4  3.3 2.9  1.9 3.6  3.9 0.56
Length of procedure (min), mean  SD 75  30 80  30 71  29 0.35
Length of hospital stay (days), mean  SD 2.5  3 2.9  2.2 2.3  3.4 0.53
ABI ¼ ankle brachial index.
a t-test or ManneWhitney test for continuous variables, chi-square or Fisher exact test for categorical variables.
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the statistical analysis. The same methodology was used by
the independent core laboratory in its analysis and by
others in a landmark study at the coronary level16 whereas
in most studies on femoropopliteal stenting, we only notice
the absence of details for this speciﬁc aspect.2,6,14,17
Variations are also observed in the literature depending
on the classiﬁcation used to report stent fractures. For
example, in the Fast and Vienna studies no speciﬁc stent
fractures classiﬁcation was used.2,14 In the SIROCCO trial,
stent fracture was deﬁned as “1 broken strut”.5 Scheinert
and al.4 considered the types 3 and 4 as “severe fractures”.
Moreover, follow-up protocols lead to wide differences
among studies. Some studies are based on biplane X-ray
with maximal magniﬁcation and zoom whereas other
studies report on non-systematic single-view X-ray.2,6,14,18Besides, some studies rely on independent laboratory
expertise while others do not. Analysis of type 1 or type 2
fractures is challenging and underestimation of these frac-
tures types would dramatically decrease the reported stent
fracture rates. Consequently, all the aforementioned factors
result in great discrepancies between the reported rates of
stent fractures in the literature and efforts should be made
to improve the reproducibility of protocols and analysis of
stent fracture assessment. In particular, serial X-rays should
be realized with at least two different projections in DICOM
ﬁles. Incidence of stent fracture varies considerably ac-
cording to the stent characteristics. In the present study
only self-expanding LifeStent (C.R. Bard Vascular) was
implanted. In others studies where different brands of stent
were used, differences were observed according to the type
of nitinol stents, with some nitinol stents doing better than
Table 3. Morphological and clinical details of the fractured stents.
Fracture Type of
fracture
Fractured
stent
Stent
location
Fracture
location
Stent Ø Degree of
calciﬁcation
Number of
overlap
Stent length/
total stented
length
Clinical
impact/
baseline
ISR/
thrombosis
Management 1 year
outcome
1 2 4th/4 Dist SFA
P1
Dist SFA* 6 mild 3 170/480 IC/IC ISR TLR Asympto
2 2e2 2nd/2 P1-P2-P3 P1*,** 6 sev 1 80/250 Asympto 0 e Asympto
3 1 1 Mid-Dist SFA
P1
Dist SFA** 6 mod 0 150/150 Asympto 0 e Asympto
4 2 2nd/3 Prox-Mid-Dist
SFA
Mid SFA* 7 mild 2 170/400 IC/IC ISR TLR Asympto
5 4e4 3rd/3 Dist SFA
P1-P2-P3
Dist SFA*
P1**
6 mod 2 170/470 IC/CLI ISR TLR Asympto
6 2e3 2nd/2 Mid-dist SFA
P1-P2
Dist SFA**
P1***
6 sev 1 170/340 Asympto ISR e Asympto
7 3 3rd/3 Mid-Dist SFA
P1
Mid SFA* 7 sev 0 170/370 Asympto ISR e Asympto
8 3 1 Dist SFA
P1-P2-P3
P1* 6 sev 0 170/170 Asympto 0 e Asympto
9 3 1st/2 Prox-Mid SFA Prox SFA* 7 sev 1 150/320 Asympto 0 e Asympto
10 2 1st/2 Mid-Dist SFA Dist SFA*** 7 sev 1 80/200 Asympto 0 e Asympto
11 2 2nd/2 Dist SFA
P1
Dist SFA* 7 sev 1 120/200 Asympto 0 e Asympto
12 4e4 1 Mid-Dist SFA
P1
Dist SFA**
P1***
7 mod 0 170/170 Asympto 0 e Asympto
13 2 3rd/3 Mid-Dist SFA Mid SFA* 7 mod 2 170/390 Asympto 0 e Asympto
14 3 1 Mid-Dist SFA
P1
Dist SFA*** 6 mild 0 170/170 Asympto 0 e Asympto
15 4e4 2nd/3 Mid-Dist SFA
P1
Dist
SFA**,***
6 sev 2 170/270 IC/CLI Thrombosis e Not improved
16 2 2nd/3 Prox-Mid-Dist
SFA
Prox SFA* 6 sev 2 170/380 Asympto 0 e Asympto
Type of fracture ¼ type of stent fracture according to the Jaff classiﬁcation.10 When several fractures were identiﬁed on the same stent the different types were reported: Fractured
stent ¼ indicate the rank of the fractured stent in case of multiple stent implantation (from proximal to distal); Stent location ¼ anatomical location of the fractured stent
(Prox ¼ proximal; Mid ¼ mid; Dist ¼ distal part of the superﬁcial femoral artery (SFA) and P1 ¼ above the knee popliteal artery; P2 ¼ popliteal artery at the level of the knee-joint;
P3 ¼ below-the-knee popliteal artery); Fracture location ¼ anatomical location of the fracture.*, **, *** ¼ indicate that the proximal; mid or distal portion of the stent was fractured;
respectively; Stent Ø ¼ diameter of the fractured stent (mm); Degree of calciﬁcation ¼ mild; mod ¼ moderate; sev ¼ severe vascular calciﬁcation in regard of the fractured stent;
Number of overlap ¼ total number of overlap (s); Stent length/total stented length ¼ length of the fractured stent normalized to the total stented length (mm); Clinical impact/
baseline ¼ clinical status of the limb in which the fracture occurred in comparison to baseline status (IC ¼ intermittent claudication; Asympto ¼ asymptomatic; CLI ¼ critical limb
ischemia); ISR/thrombosis/0 ¼ indicate if the fracture was associated with an in-stent restenosis (ISR) or a stent thrombosis or no event (0); Management ¼ indicate if the patient
underwent a new procedure (TLR ¼ target lesion revascularization); 1 year outcome ¼ clinical status of the limb at the one-year follow up point (Asympto ¼ asymptomatic).
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Figure 2. Details and X-ray illustrations of the different types of stent fractures observed and classiﬁed according to the Jaff et al.10
classiﬁcation.
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available stents exhibit a variable ability to withstand
chronic deformation depending on the type of deformation
(axial compression or bending deformation) and the type of
stent design. In the same study, the LifeStent was found to
be more susceptible to axial stress but much more resistant
to bending deformation.21 In the Resilient trial, the LifeStent
demonstrated a low fracture rate.17 Stent resistance to
chronic fatigue could explain the differences observed be-
tween the stents. However, incidence of stent fractures
does not seem to increase with the length of follow-up. In
the Vienna study, though stent fractures were not system-
atically sought at 24 months, no new stent fractures were
detected in patients undergoing reinterventions between
the 12th and the 24th months.2 Likewise, in the Resilient
trial, the overall incidence of fractures was 3.1% at 1 year
(n ¼ 9) and 4.1% at 3 years (n ¼ 12).17 Only three new
fractures were identiﬁed from the 12- to 18-month radio-
graphs. Consequently, fatigue of the devices does not seem
to be the unique factor impacting on stent fractures. The
LifeStent is a ﬂexible stent made of multiple helical struts
with angled helical bridges. As for other second-generationnitinol stents, great improvements have been achieved in
the design of these stents with a reduced number of cell
interconnections and the spiral form of these in-
terconnections. These improvements have resulted in more
ﬂexibility in the axial direction and a greater ability to
withstand bending stress, torsion, and external compres-
sion. The use of these new stents translated in reduced
stent fracture rates but no strong evidence of the superi-
ority of one stent design over another in terms of clinical
outcomes has been made so far. Another determinant
factor regarding the onset of stent fractures is the length of
the stented segment.4,20 Scheinert et al.4 reported that
fracture rate increased dramatically with the stented length:
13% for stented length < 8 cm, 42.4% for stented length
between 8 cm and 16 cm, and 52.0% for stented length
>16 cm. In our study, the median total stented length was
240  180 mm. Recently, Bosiers et al.6 reported a low rate
of fractures using protégé Everﬂex in TASC C and D lesions.
In this study the mean lesion length was similar to our data
(242 mm vs. 235 mm). However, the authors reported a 6%
rate of stent fractures. This low rate was not expected, given
the results published in the Durability I study.18 In this
Table 4. Detailed characteristics of the implanted stents.
Overall, n ¼ 90 Fracture, n ¼ 16 No fracture, n ¼ 74 p-Valuea
Stent length (mm), median  IQR 150  90 170  10 120  90 0.02
Stent length (mm), n (%) 0.005
¼170 38 (42%) 12 (75%) 26 (35%)
<170 52 (58%) 4 (25%) 48 (65%)
150 10 (11.1%) 2 (12.5%) 8 (10.9%)
120 10 (11.1%) 1 (6.3%) 9 (12.2%)
100 6 (6.7%) 0 (0%) 6 (8.1%)
80 26 (28.9%) 1 (6.3%) 25 (33.8%)
Overlap, n (%) 0.43
0 20 (22%) 5 (31%) 15 (20%)
1 36 (40%) 7 (44%) 29 (39%)
2 34 (38%) 4 (25%) 30 (41%)
Total stented length (mm), n (%) 0.89
150e250 35 (38.9%) 7 (43.8%) 28 (37.8%)
260e350 24 (26.7%) 3 (18.8%) 21 (28.4%)
360e450 18 (20%) 4 (25%) 14 (18.9%)
>450 13 (14.4%) 2 (12.5%) 11 (14.9%)
Number of stent (s), n (%) 0.25
1 11 (12%) 4 (25%) 7 (9%)
2 30 (33%) 5 (31%) 25 (34%)
3 45 (50%) 6 (38%) 39 (53%)
4 4 (4%) 1 (6%) 3 (4%)
Stent diameter (mm), n (%) 0.01
7 18 (20%) 7 (44%) 11 (15%)
6 72 (80%) 9 (56%) 63 (85%)
Calciﬁcations 0.64
mild 22 (24%) 3 (19%) 19 (26%)
moderate 27 (30%) 4 (25%) 23 (31%)
severe 41 (46%) 9 (56%) 32 (43%)
Stent location
Proximal SFA, n (%) 38 (43%) 3 (20%) 35 (47%) 0.08
Mid SFA, n (%) 62 (69%) 11 (69%) 51 (69%) 0.6
Distal SFA, n (%) 57 (63%) 15 (94%) 42 (57%) 0.005
P1, n (%) 33 (37%) 10 (63%) 23 (31%) 0.02
P2, n (%) 12 (13%) 3 (19%) 9 (12%) 0.44
P3, n (%) 6 (7%) 2 (13%) 4 (5%) 0.29
Stent length ¼ length of each stent; Overlap ¼ number of overlap for each stent; SFA ¼ superﬁcial femoral artery; P1 ¼ proximal (above
the knee) portion of the popliteal artery; P2 ¼mid portion (across the knee) of the popliteal artery; P3 ¼ distal (below the knee) portion of
the popliteal artery.
a ManneWhitney test for continuous variables, chi-square or Fisher exact test for categorical variables.
J.M. Davaine et al. 209study, only one stent implantation was allowed using pro-
tégé Everﬂex, thus excluding overlap between stents, which
is considered to increase stent fractures incidence.4,5 The
mean lesion length was shorter (96.4 mm) and the fracture
rate was higher (8.1%). The authors explained thisTable 5. Multivariate analysis of stent fracture predictive factors.
Variables Odds
ratio (OR)
95% CI p-Value
Stent diameter (7 vs. 6 mm) 18.9 2.7e133 0.04
P1 stent implantation
(yes vs. no)
4.8 0.9e27 0.07
Distal SFA stent implantation
(yes vs. no)
11.8 1.01e138 0.05
Number of stents (addition of
one more stent)
0.7 0.3e1.6 0.41
Stent length
(¼170 vs. <170 mm)
3.1 0.7e14 0.14discrepancy between both studies by stent elongation that
occurred in 90% of the stent fractures in Durability I. Like-
wise, in the Resilient trial the mean stented length and stent
fracture rate were 99.2 mm and 3.1%, respectively,Table 6. Multivariate analysis of intrastent restenosis predictive
factors.
Variables Odds
ratio (OR)
95% CI p-Value
Number of stents
(addition of one
more stent)
2.5 0.2e32.5 0.48
Age 1.002 0.9e1.2 0.98
TASC C vs. D 30.7 0.2e1000 0.19
Female vs. male 0.4 0.004e44 0.71
Calciﬁcations
(severe vs.
mild þ moderate)
16.3 0.4e699 0.14
Fracture (no vs. yes) 1.2 0.1e24.4 0.91
Figure 4. Primary (A) and secondary (B) patency. According to
KaplaneMeier estimates, primary patency was 60% in the group
with stent fractures and 74.1% in the group without stent fractures
(A) while secondary patency was 80% and 88.2%, respectively (B).
Figure 3. Primary (A) and secondary (B) sustained clinical improve-
ment. According to KaplaneMeier estimates, 1-year primary sus-
tained clinical improvement was 80% in the group with stent
fractures and 74.1% in the group without stent fractures (A). Sec-
ondary sustained clinical improvement was 91.6% in the group with
stent fractures and 91.7% in the group without stent fractures (B).
210 European Journal of Vascular and Endovascular Surgery Volume 46 Issue 2 August/2013compared with 269.5 mm and 35.7% in our study, which,
again, highlights the critical inﬂuence of the length of the
stented segment.17 Among other factors that can be held
accountable for stent fractures are multiple stent deploy-
ment with overlap between stents and involvement of the
popliteal artery.21 In this study, a mean of 2.1 stents wasused per procedure and no fractures were noted in the
overlap zones. This observation may be in accordance with
this notion since overlap dramatically increases the axial
stiffness of the stented segment and may increase the risk
of fracture outside the overlap zone itself. Here, stent im-
plantation in the distal part of the SFA was found to
signiﬁcantly impact on stent fractures (p ¼ .05). Similarly,
stent implantation in the proximal (P1) popliteal artery
showed a tendency towards the onset of stent fractures but
did not reach statistical signiﬁcance (p ¼ .07). The distal part
J.M. Davaine et al. 211of the SFA is a segment where high mechanical stress is
present and where the stents are submitted to important
external compression. In this tortuous environment, stents
fractures are more likely to occur. In contrast, in the Resilent
trial only 7% of the lesions were located at the level of the
proximal popliteal artery and in the Durability-200 study
popliteal involvement was noted in 27% of the lesions.6,17
Large stent diameter (7 mm vs. 6 mm) was also found to
signiﬁcantly inﬂuence the rate of stent fractures in our
analysis. To our knowledge, no clear answer that could
explain this observation is given in the literature; therefore,
this observation warrants further study. Finally, the clinical
presentation of our patients seems more severe than in
Durability-200 since 62% presented with CLI (vs. 29% in
Durability-200) which is consistent with the high popliteal
involvement and the lack of re-entry.Clinical impact of stent fractures
Controversy remains in the literature as to whether stent
fractures are associated with restenosis, occlusion, and
clinical deterioration.3e5,19,20 Noteworthy, in this cohort, we
did not identify any signiﬁcant impact of stent fractures in
terms of clinical deterioration and patency. Primary and
secondary sustained clinical improvement rates were 80%,
74.1%, and 91.6%, 91.7% in the group of limbs with and
without stent fractures, respectively (Fig. 3A, B). Accord-
ingly, primary and secondary patency rates were 60%,
74.1%, and 80%, 88.2% in the groups with and without
stent fractures, respectively (Fig. 4A, B). Landmark studies
found that stent fractures were associated with high rates
of ISR and reocclusions4,22,23 while others did not.5,19,24
However, in most studies, attention was given to ISR and
reocclusion, and the clinical implication was barely
mentioned. Most importantly, no details were given on the
secondary procedures and on the outcome following rein-
terventions. The close follow-up of patients conducted in
our study resulted in early-detection of ISR and clinical
deterioration. Asymptomatic patients were closely moni-
tored and ISR-related symptoms were treated. Supporting
this notion, Schlager et al.20 reported 27.6% and 1.8% of
stent fractures in their study comparing two different nitinol
stents (p < .001) but at the same time no difference was
noted in terms of restenosis (p ¼ .59) and clinical deterio-
ration (p ¼ .47) between the two nitinol stent groups. The
authors stated that they found substantial rates of ISR but
with only very few patients suffering clinical deterioration.
They also noted that stent fractures were different among
stent brands and seemed to be a minor problem with
certain stent designs. Moreover, the most recent of these
studies was published in 2007 and considering the signiﬁ-
cant advances made in the endovascular ﬁeld in this period
of time these data need to be updated. Stent fractures
analysis showed one type 1, seven type 2, ﬁve type 3, and
three type 4 stent fractures. No type of stent fracture has
been identiﬁed as more prone to induce clinical deteriora-
tion or ISR because possibly due to a lack of statistical po-
wer. However major types 3 and 4 are usually suspected tobe more deleterious in terms of clinical consequences. Of
note, our statistical analysis found that cerebrovascular
disease was more frequent in the group of patients with
stent fractures. We cannot see any clear association what-
soever between both factors.We believe this is the result of
statistical analysis ﬂuctuation, and in this case the associa-
tion is irrelevant, or the result of the presence of a con-
founding factor.Study limitations
A larger sample of patients and a control group would have
provided this study greater statistical signiﬁcance. In
particular, a larger study could address the clinical inﬂuence
of fractures according to their types. Of the 134 stents
implanted only 90 (67%) were available for analysis, mostly
because of the 10 patients for whom X-ray data were not
suitable for CoreLab software analysis. Other reasons for
this discrepancy were that ﬁve patients died during follow-
up, two were lost to follow up, two were in palliative
treatment, and one patient underwent a major amputation
before X-ray. The follow-up protocol was based on clinical
and Doppler examinations. New techniques such as intra-
vascular ultrasound or optical computed tomography (OCT)
or even three-dimensional OCT image reconstruction are
promising tools to improve follow-up. Several reports have
shown promising results at the coronary level. These chal-
lenging techniques are able to detect useful parameters
such as late lumen loss, stent fractures or stent malaposi-
tion.25e27 Finally, X-ray assessment protocol was scheduled
for a single control at 12 months. Serial X-ray evaluation
would have shed light concerning the association between
stent fractures and ISR.
CONCLUSION AND PERSPECTIVES
This study showed that long length stenting of SFA is
associated with a high rate of stent fracture but that the
clinical impact of these fractures is low. No positive corre-
lation between stent fracture and ISR has been identiﬁed.
Moreover, in case of stent fracture, ISR and/or symptom
resurgence, the redo endovascular procedure is still an
option and is successful in the majority of the cases with
low additional morbidity. This attitude should be based on a
close follow-up, in particular during the ﬁrst year after
treatment. This study has focused on self-expendable
stents. However, other interesting therapeutic strategies
such as covered stents or bioabsorbable stents should also
be assessed for their potential to limit the clinical conse-
quence of stent fracture.28e30 Our data highlight that the
clinical impact of stent fracture has still to be elucidated.
Our results mandate the need for a larger study population
with serial X-ray and Doppler-examinations and a longer
follow-up period to compare outcomes of patients accord-
ing to stent fractures. The primary end point should focus
on clinical symptoms of patients. Such a study would be of
great interest in the understanding of the clinical impact of
stent fractures in SFA treatment and would pave the way
for high-level evidence guidelines.
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